Natixis Advisors LLC Buys 866,070 Shares of Haleon plc (NYSE:HLN)

Natixis Advisors LLC lifted its stake in shares of Haleon plc (NYSE:HLN - Free Report) by 142.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,473,767 shares of the company's stock after purchasing an additional 866,070 shares during the period. Natixis Advisors LLC's holdings in Haleon were worth $15,593,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of HLN. Huntington National Bank boosted its stake in shares of Haleon by 7.0% during the 3rd quarter. Huntington National Bank now owns 39,084 shares of the company's stock worth $414,000 after acquiring an additional 2,568 shares in the last quarter. WCM Investment Management LLC lifted its position in shares of Haleon by 36.6% during the 3rd quarter. WCM Investment Management LLC now owns 158,765 shares of the company's stock worth $1,694,000 after purchasing an additional 42,530 shares during the last quarter. Chartwell Investment Partners LLC lifted its position in shares of Haleon by 107.8% during the 3rd quarter. Chartwell Investment Partners LLC now owns 475,415 shares of the company's stock worth $5,030,000 after purchasing an additional 246,594 shares during the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Haleon by 55.6% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 480,760 shares of the company's stock worth $5,087,000 after purchasing an additional 171,877 shares during the last quarter. Finally, Axxcess Wealth Management LLC lifted its position in shares of Haleon by 2.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 63,843 shares of the company's stock worth $675,000 after purchasing an additional 1,450 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. UBS Group raised Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. The Goldman Sachs Group lowered Haleon from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research note on Tuesday, August 6th. They issued a "buy" rating on the stock. Finally, Morgan Stanley raised their price objective on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $10.95.

Haleon Stock Performance

Shares of NYSE HLN remained flat at $9.48 during midday trading on Wednesday. 5,035,138 shares of the stock were exchanged, compared to its average volume of 5,287,197. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock's fifty day moving average price is $10.06 and its 200 day moving average price is $9.36. The firm has a market cap of $42.91 billion, a P/E ratio of 27.91, a P/E/G ratio of 2.84 and a beta of 0.30.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.